These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 17431213)

  • 1. Exendin-4, but not dipeptidyl peptidase IV inhibition, increases small intestinal mass in GK rats.
    Simonsen L; Pilgaard S; Orskov C; Rosenkilde MM; Hartmann B; Holst JJ; Deacon CF
    Am J Physiol Gastrointest Liver Physiol; 2007 Jul; 293(1):G288-95. PubMed ID: 17431213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice.
    Kissow H; Hartmann B; Holst JJ; Viby NE; Hansen LS; Rosenkilde MM; Hare KJ; Poulsen SS
    Regul Pept; 2012 Nov; 179(1-3):91-100. PubMed ID: 22989472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An overview of once-weekly glucagon-like peptide-1 receptor agonists--available efficacy and safety data and perspectives for the future.
    Madsbad S; Kielgast U; Asmar M; Deacon CF; Torekov SS; Holst JJ
    Diabetes Obes Metab; 2011 May; 13(5):394-407. PubMed ID: 21208359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential importance of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide 1 receptor signaling for beta cell survival in mice.
    Maida A; Hansotia T; Longuet C; Seino Y; Drucker DJ
    Gastroenterology; 2009 Dec; 137(6):2146-57. PubMed ID: 19766644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term metabolic benefits of exenatide in mice are mediated solely via the known glucagon-like peptide 1 receptor.
    Tatarkiewicz K; Sablan EJ; Polizzi CJ; Villescaz C; Parkes DG
    Am J Physiol Regul Integr Comp Physiol; 2014 Apr; 306(7):R490-8. PubMed ID: 24477544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors.
    Holst JJ
    Expert Opin Emerg Drugs; 2004 May; 9(1):155-66. PubMed ID: 15155141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liraglutide: the therapeutic promise from animal models.
    Knudsen LB
    Int J Clin Pract Suppl; 2010 Oct; (167):4-11. PubMed ID: 20887299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
    Deacon CF; Mannucci E; Ahrén B
    Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. No evidence of drug-induced pancreatitis in rats treated with exenatide for 13 weeks.
    Tatarkiewicz K; Belanger P; Gu G; Parkes D; Roy D
    Diabetes Obes Metab; 2013 May; 15(5):417-26. PubMed ID: 23163898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.
    Pinelli NR; Hurren KM
    Ann Pharmacother; 2011 Jul; 45(7-8):850-60. PubMed ID: 21730278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dipeptidyl peptidase 4 inhibitor sitagliptin protects endothelial function in hypertension through a glucagon-like peptide 1-dependent mechanism.
    Liu L; Liu J; Wong WT; Tian XY; Lau CW; Wang YX; Xu G; Pu Y; Zhu Z; Xu A; Lam KS; Chen ZY; Ng CF; Yao X; Huang Y
    Hypertension; 2012 Sep; 60(3):833-41. PubMed ID: 22868389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroprotective effect of the glucagon-like peptide-1 receptor agonist, synthetic exendin-4, in streptozotocin-induced diabetic rats.
    Liu WJ; Jin HY; Lee KA; Xie SH; Baek HS; Park TS
    Br J Pharmacol; 2011 Nov; 164(5):1410-20. PubMed ID: 21323903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The peptide-hormone glucagon-like peptide-1 activates cAMP and inhibits growth of breast cancer cells.
    Ligumsky H; Wolf I; Israeli S; Haimsohn M; Ferber S; Karasik A; Kaufman B; Rubinek T
    Breast Cancer Res Treat; 2012 Apr; 132(2):449-61. PubMed ID: 21638053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Umami receptor activation increases duodenal bicarbonate secretion via glucagon-like peptide-2 release in rats.
    Wang JH; Inoue T; Higashiyama M; Guth PH; Engel E; Kaunitz JD; Akiba Y
    J Pharmacol Exp Ther; 2011 Nov; 339(2):464-73. PubMed ID: 21846840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of leptin replacement alone and with exendin-4 on food intake and weight regain in weight-reduced diet-induced obese rats.
    Reidelberger R; Haver A; Chelikani PK; Apenteng B; Perriotte-Olson C; Anders K; Steenson S; Blevins JE
    Am J Physiol Endocrinol Metab; 2012 Jun; 302(12):E1576-85. PubMed ID: 22510712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the beta-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4.
    Tourrel C; Bailbe D; Lacorne M; Meile MJ; Kergoat M; Portha B
    Diabetes; 2002 May; 51(5):1443-52. PubMed ID: 11978641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term exendin-4 treatment delays natural deterioration of glycaemic control in diabetic Goto-Kakizaki rats.
    Simonsen L; Pilgaard S; Orskov C; Hartmann B; Holst JJ; Deacon CF
    Diabetes Obes Metab; 2009 Sep; 11(9):884-90. PubMed ID: 19508463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dipeptidyl peptidase IV inhibition prevents the formation and promotes the healing of indomethacin-induced intestinal ulcers in rats.
    Inoue T; Higashiyama M; Kaji I; Rudenkyy S; Higuchi K; Guth PH; Engel E; Kaunitz JD; Akiba Y
    Dig Dis Sci; 2014 Jun; 59(6):1286-95. PubMed ID: 24379150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphodiesterase-3 inhibition augments the myocardial infarct size-limiting effects of exenatide in mice with type 2 diabetes.
    Ye Y; Qian J; Castillo AC; Ling S; Ye H; Perez-Polo JR; Bajaj M; Birnbaum Y
    Am J Physiol Heart Circ Physiol; 2013 Jan; 304(1):H131-41. PubMed ID: 23103492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes.
    Mikhail N
    Expert Opin Investig Drugs; 2008 Jun; 17(6):845-53. PubMed ID: 18491986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.